Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
Delayed Swiss Exchange  -  11:30 2022-11-30 am EST
101.00 CHF   +2.33%
11/15Global markets live: Amazon, Berkshire Hathaway, Infineon, Home Deport Walmart...
MS
11/15Medacta Settles Patent Disputes Over Knee, Shoulder Implants With Conformis
MT
11/15Medacta Group SA announces the final settlement in the Conformis case
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution

09/21/2022 | 01:02pm EST

Medacta Group SA / Key word(s): Market Launch
Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution

21.09.2022 / 19:00 CET/CEST


 

Media release


Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution

CASTEL SAN PIETRO, Switzerland, September 21, 2022 – Medacta announced today the completion of the first revision surgeries in the US using MyKnee® R, the game-changing technology for streamlining and guiding total knee revision surgeries where even highly experienced surgeons can face complex and time-consuming procedures.

One of the most challenging aspects of revision knee arthroplasty is the detection of anatomic landmarks for proper positioning of the new implant. I found the MyKnee R preoperative planning capability incredibly useful in eliminating many of the surprises that we encounter intraoperatively,” says Jay Patel, D.O., at Atlanta Orthopaedic Institute, Atlanta, GA, USA.

MyKnee R provides personalized 3D interactive preoperative planning and a set of 3D-printed guide blocks. These guides are placed directly on the existing primary implant in situ to guide the placement of new implants from Medacta’s comprehensive knee portfolio, ranging from a lower level of constraint (GMK® Sphere and GMK® Primary) to semi- and fully constrained solutions (GMK® Revision and GMK® Hinge). These implants are part of a synergistic system that allows for intraoperative flexibility and are available with the SensiTiN™ ceramic-like coating, an option designed for reduced metal ion release.

With MyKnee R, it is also possible to plan the position of the GMK System’s revision options (i.e., 3D Metal cones, extension stems, offsets, and augments), addressing the high variation in knee revision scenarios with maximized versatility.

“Revision TKA can present many intraoperative surgical challenges, primarily due to substantial bone loss at the distal femur and/or proximal tibia. The unique ability to preoperatively plan and, most importantly, visualize the positioning, orientation, and sizing of revision constructs with MyKnee R has been extremely helpful in anticipating, evaluating, and treating some of these intraoperative hurdles,” says Kris J. Alden, M.D., Ph.D., at the Illinois Bone & Joint Institute, USA.

MyKnee R is part of the MySolutions Personalized Ecosystem, Medacta’s advanced network of digital solutions designed to improve patient outcomes and healthcare efficiency. Together with a comprehensive implant portfolio, from unicompartmental to hinged systems, MySolutions empowers Medacta’s holistic approach to personalized medicine, bringing value at every step throughout the entire patient journey.

MyKnee R is also supported by the comprehensive, tailored educational offering provided by the M.O.R.E. Institute. With an international network of expert surgeons, the M.O.R.E. Institute is at the forefront of education on total knee replacement techniques and products with personalized high-level educational pathways. With Medacta the surgeon is never alone.

Discover more about MyKnee R and Medacta’s knee portfolio.

 

 

 

Contact

Medacta International SA

Gianluca Olgiati

Senior Director Global Marketing

Phone: +41 91 696 60 60

media@medacta.ch

 

About Medacta

Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon experts globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.

https://www.medacta.com

 

 


Additional features:

File: Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R


End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1447661

 
End of News EQS News Service

1447661  21.09.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1447661&application_name=news&site_id=zonebourse_sftp

ę EQS 2022
All news about MEDACTA GROUP SA
11/15Global markets live: Amazon, Berkshire Hathaway, Infineon, Home Depo..
MS
11/15Medacta Settles Patent Disputes Over Knee, Shoulder Implants With Conformis
MT
11/15Medacta Group SA announces the final settlement in the Conformis case
EQ
11/06Medacta Says First US Hip Surgery Carried Out With Double Mobility Converter
MT
11/04Medacta Group Sa : Medacta Expands its Hip Offerings with New Cobalt-Free SensiTiN™ ..
EQ
10/12Medacta NextAR Spine wins the 2022 Spine Technology Award from Orthopedics This Week du..
EQ
10/05Medacta's MySpine Anchor Technology Used in First US Procedure
MT
10/05Medacta announces the first MySpine Anchor procedure completed in the US
EQ
09/21Medacta's MyKnee R Platform Becomes Part Of Revision Surgeries In US
MT
09/21Medacta announces first revision surgeries in the US using the unique-on-the-market and..
EQ
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Financials
Sales 2022 429 M 444 M 444 M
Net income 2022 56,2 M 58,1 M 58,1 M
Net Debt 2022 123 M 127 M 127 M
P/E ratio 2022 35,6x
Yield 2022 0,59%
Capitalization 2 050 M 2 124 M 2 120 M
EV / Sales 2022 5,07x
EV / Sales 2023 4,43x
Nbr of Employees 1 421
Free-Float 30,4%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 100,27 €
Average target price 107,65 €
Spread / Average Target 7,36%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Non-Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA-30.49%2 071
ABBOTT LABORATORIES-25.12%183 075
MEDTRONIC PLC-26.41%101 730
BECTON, DICKINSON AND COMPANY-3.43%68 299
DEXCOM, INC.-17.77%42 639
HOYA CORPORATION-16.07%36 984